The ROE (Return on Equity) of Vertex Pharmaceuticals Incorporated (VRTX) is
21.18%.
ROE (Return on Equity) shows how effectively a company utilizes shareholders equity to produce earnings. It serves as a key indicator of financial return for investors.
| Date |
Value |
| 2025-12-31 |
21.18%
|
| 2024-12-31 |
-3.26%
|
| 2023-12-31 |
20.59%
|
| 2022-12-31 |
23.88%
|
| 2021-12-31 |
23.19%
|
| 2020-12-31 |
31.22%
|
| 2019-12-31 |
19.34%
|
| 2018-12-31 |
47.28%
|
| 2017-12-31 |
12.99%
|
| 2016-12-31 |
-9.69%
|
| Ticker |
Name |
Value |
|
XNCR
|
Xencor, Inc.
|
-14.46%
|
|
BBIO
|
BridgeBio Pharma, Inc.
|
-774.99%
|
|
CBPO
|
China Biologic Products Holdings Inc
|
7.68%
|
|
EDIT
|
Editas Medicine, Inc.
|
-586.56%
|
|
MORF
|
Morphic Holding Inc
|
-21.82%
|
|
NBIX
|
Neurocrine Biosciences, Inc.
|
14.71%
|
|
NTRA
|
Natera, Inc.
|
-12.16%
|
|
ALXN
|
Alexion Pharmaceuticals Inc
|
5.18%
|
|
AMRN
|
Amarin Corporation PLC
|
-8.45%
|
|
VIR
|
Vir Biotechnology, Inc.
|
-57.23%
|
|
ARWR
|
Arrowhead Pharmaceuticals, Inc.
|
-1439.40%
|
|
PTCT
|
PTC Therapeutics, Inc.
|
-332.49%
|
|
BCRX
|
BioCryst Pharmaceuticals, Inc.
|
-284.33%
|
|
EXAS
|
Exact Sciences Corporation
|
-8.66%
|
|
VCEL
|
Vericel Corporation
|
4.66%
|
|
AGIO
|
Agios Pharmaceuticals, Inc.
|
-34.60%
|
|
ALLK
|
Allakos LLC
|
-146.95%
|
|
INSM
|
Insmed Incorporated
|
-172.78%
|
|
MYGN
|
Myriad Genetics, Inc.
|
-99.43%
|
|
BIIB
|
Biogen Inc.
|
7.08%
|
|
EXEL
|
Exelixis Inc
|
36.21%
|
|
NVAX
|
Novavax, Inc.
|
-66.69%
|
|
OPK
|
OPKO Health, Inc.
|
-17.80%
|
|
ORGO
|
Organogenesis Holdings Inc.
|
8.53%
|
|
SRNE
|
Sorrento Therapeutics Inc
|
3079.57%
|
|
TWST
|
Twist Bioscience Corporation
|
-14.66%
|
|
ACAD
|
Acadia Pharmaceuticals Inc.
|
31.86%
|
|
BMRN
|
BioMarin Pharmaceutical Inc.
|
5.73%
|